Exelixis EXEL Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's accounts payable?
- Exelixis (EXEL) reported accounts payable of $24.15M in Q1 2026.
- How has Exelixis's accounts payable changed year-over-year?
- Exelixis's accounts payable decreased by 43.6% year-over-year, from $42.84M to $24.15M.
- What is the long-term trend for Exelixis's accounts payable?
- Over 5 years (2020 to 2025), Exelixis's accounts payable has grown at a 4.6% compound annual growth rate (CAGR), from $23.63M to $29.62M.
- What does accounts payable mean?
- The total amount of money the company owes to its suppliers for goods and services purchased on credit.
- How do you interpret accounts payable?
- An increase may suggest improved cash flow management by delaying payments, while a decrease may indicate faster settlement of obligations or reduced purchasing activity.
- How does accounts payable compare across companies?
- Standard across all industries; peers in biopharma typically maintain consistent payable cycles relative to their R&D and manufacturing spend.